Comparison of dosimetric characteristics and longitudinal urinary tract symptom changes between high-dose-rate and low-dose-rate brachytherapy combined with external beam radiation therapy for prostate cancer.
T. Sakurai, S. Takamatsu, Tomoyuki Makino, Risako Minamikawa, Akihito Okubo, Kenta Nishimura, R. Naito, H. Yaegashi, Atsushi Mizokami, Satoshi Kobayashi
2026.2.1Brachytherapy
Paper details
- Journal
- Brachytherapy
- Published
- 2026.2.1
- Citations
- 0
- References
- 23
- Fields
- Medicine, Engineering
tlooto Summary
HDR-BT has less interpatient variability and faster recovery, and higher uD10 in LDR-BT predicts LUTS deterioration, which is associated with earlier return to baseline of IPSS.
Abstract
PURPOSE Few comparative studies have evaluated longitudinal changes in International Prostate Symptom Score (IPSS) between low-dose-rate brachytherapy (LDR-BT) and high-dose-rate brachytherapy (HDR-BT) in the setting of combined modality treatment. We aimed to compare the dosimetric characteristics and longitudinal changes in lower urinary tract symptoms (LUTS) and urinary quality of life (uQOL) between HDR-BT and LDR-BT, both combined with external beam radiation therapy (EBRT), for prostate cancer, and identify LUTS deterioration predictors.
METHODS AND MATERIALS We retrospectively evaluated 200 patients treated with HDR-BT (13 Gy, n = 125) or LDR-BT (110 Gy, n = 75) (EBRT 44-46/45 Gy) between 2010 and 2023. Dosimetric parameters included clinical target volume (CTV) D90, V100 and V150, urethral D10 and D30 (uD10/uD30), and total biologically effective dose (BED). LUTS and uQOL were assessed using the IPSS.
RESULTS CTV D90, V150, uD10/30, and total BED3.0/10.0 were significantly higher with LDR-BT; total BED1.5 was significantly higher with HDR-BT (all P<0.001). Interpatient variability in dosimetric parameters was significantly greater in LDR-BT (p < 0.05). Compared with LDR-BT, HDR-BT was associated with earlier return to baseline of IPSS (9 months vs 18 months), irritative-IPSS (i-IPSS; 6 months vs 12 months), uQOL (6 months vs 18 months), and obstructive-IPSS (o-IPSS; 9 months vs 18 months). Adjuvant hormonal therapy was associated with smaller o-IPSS increase in HDR-BT (p = 0.029). In LDR-BT, uD10 was associated with greater i-IPSS increase (p = 0.018); uD10 <150% was associated with earlier return to baseline of symptom scores.
CONCLUSIONS HDR-BT has less interpatient variability and faster recovery. Higher uD10 in LDR-BT predicts LUTS deterioration.
Citation format
SAKURAI, T., et al. Comparison of dosimetric characteristics and longitudinal urinary tract symptom changes between high-dose-rate and low-dose-rate brachytherapy combined with external beam radiation therapy for prostate cancer. Brachytherapy, 2026, 25(3): 515–524.